指南与共识肾小球疾病

KDOQI对美国KDIGO 2024 ANCA相关血管炎管理指南的解读

KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
指南 / 共识 · Am J Kidney Dis · 2026-01-01

KDOQI工作组审查了KDIGO 2024年ANCA相关血管炎管理临床实践指南,并为美国临床实践提供实施视角。总体上,KDOQI工作组同意KDIGO指南的大部分声明,并在解读中提供澄清和额外考虑要点。

要点

  • KDOQI工作组同意KDIGO指南的大部分声明
  • 解读提供在美国临床实践中实施的澄清和额外考虑
  • 重点在于ANCA相关血管炎的管理实践要点

核心结论

  • KDOQI工作组同意KDIGO指南的大部分声明,并为美国临床实践提供实施视角。

研究设计与样本

  • KDOQI召集工作组审查KDIGO 2024年ANCA相关血管炎管理指南声明和实践要点。

临床怎么用

  • 在美国临床实践中实施KDIGO实践要点时,需参考KDOQI工作组提供的澄清和额外考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. The KDOQI work group reviewed the Kidney Disease: Improving Global Outcomes (KDIGO) guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. Overall, the KDOQI work group agrees with the majority of the KDIGO guideline statements. Throughout this commentary, the KDOQI work group provides clarifications and additional areas for consideration when implementing these practice points.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Almaani S, Ayoub I, Geetha D, et al. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Am J Kidney Dis. 2026. PMID: 42025332. doi:10.1053/j.ajkd.2025.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。